Bicara Therapeutics Inc. (BCAX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 1.14B USD. 52-week range 13.70 to 30.99 USD. Data as of 2026-10-09.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.